Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

77 ta ish

Ish: Liposomes containing histidine overcome poly ADP-ribose polymerase inhibitor resistance

  1. On the Origin of Cancer Cells

    Otto Warbürg

    Maqola19567 iqtibos
    ABI

  2. The blockade of immune checkpoints in cancer immunotherapy

    Drew M. Pardoll

    Sharh maqolaOchiq kirish20127 iqtibos
    ABI

  3. Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines

    Peter J. Murray, Judith E. Allen, Subhra K. Biswas +22

    MaqolaOchiq kirish20144 iqtibos
    ABI

  4. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

    Padmanee Sharma, Siwen Hu‐Lieskovan, Jennifer A. Wargo +1

    Sharh maqola20174 iqtibos
    ABI

  5. PARP inhibitors: Synthetic lethality in the clinic

    Christopher J. Lord, Alan Ashworth

    Sharh maqolaOchiq kirish20173 iqtibos
    ABI

  6. Matrix Metalloproteinases: Regulators of the Tumor Microenvironment

    Kai Kessenbrock, Vicki Plaks, Zena Werb

    Sharh maqolaOchiq kirish20102 iqtibos
    ABI

  7. In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy

    Sean P. Arlauckas, Christopher Garris, Rainer H. Köhler +9

    MaqolaOchiq kirish20172 iqtibos
    ABI

  8. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

    Hannah Farmer, Nuala McCabe, Christopher J. Lord +11

    Maqola20052 iqtibos
    ABI

  9. Poly(ADP-ribose) polymerase inhibition: past, present and future

    Nicola J. Curtin, Csaba Szabó

    Sharh maqolaOchiq kirish20202 iqtibos
    ABI

  10. Transcriptional regulation of macrophage polarization: enabling diversity with identity

    Toby Lawrence, Gioacchino Natoli

    Sharh maqola20112 iqtibos
    ABI

  11. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy

    Matthew D. Vesely, Robert D. Schreiber

    MaqolaOchiq kirish20132 iqtibos
    ABI

  12. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

    Helen E. Bryant, Niklas Schultz, Huw D. Thomas +7

    Maqola20052 iqtibos
    ABI

  13. Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer

    Talia Golan, Pascal Hammel, Michele Reni +16

    Maqola20192 iqtibos
    ABI

  14. Resistance to therapy caused by intragenic deletion in BRCA2

    Stacey L. Edwards, Rachel Brough, Christopher J. Lord +6

    Maqola20082 iqtibos
    ABI

  15. Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation

    Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus +11

    Maqola20172 iqtibos
    ABI

  16. From Krebs to clinic: glutamine metabolism to cancer therapy

    Brian J. Altman, Zachary E. Stine, Chi V. Dang

    Sharh maqola20162 iqtibos
    ABI

  17. The landscape of somatic copy-number alteration across human cancers

    Rameen Beroukhim, Craig H. Mermel, Dale Porter +59

    Maqola20102 iqtibos
    ABI

  18. Histidine catabolism is a major determinant of methotrexate sensitivity

    Naama Kanarek, Heather R. Keys, Jason R. Cantor +7

    Maqola20182 iqtibos
    ABI

  19. Sarlavhasiz

    Boshqa2 iqtibos
    ABI

  20. Sarlavhasiz

    Boshqa2 iqtibos
    ABI

  21. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  22. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  23. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  24. Sarlavhasiz

    Boshqa1 iqtibos
    ABI

  25. Sarlavhasiz

    Boshqa1 iqtibos
    ABI